Antibody Protein ELISA Kit from MyBioSource header Telephone 1.858.633.0165          
1.855.MyBioSource
Fax 1.858.633.0166    Email sales@mybiosource.com 
tel/fax
menu1 Home Products Ordering Company Help menu7
bottom
   MyBioSource rightarrow Antibody rightarrow PARK2  rightarrow LOG IN  rightarrow MY ACCOUNT  rightarrow CART CONTENTS  rightarrow CHECKOUT 
horiz bar
MyBioSource Menu separator
separator
ELISA Kit ELISA Kit
CLIA Kit CLIA Kit
PCR Kit PCR Kit
Monoclonal Antibody Monoclonal Antibody
Polyclonal Antibody Polyclonal Antibody
Secondary Antibody Secondary Antibody
Antigen Antigen
Biochemical Biochemical
cDNA Clone cDNA Clone
siRNA siRNA
Peptide Peptide
Recombinant/Purified Protein Rec./Purified Protein

Custom ELISA Kit Custom ELISA Kit
Custom Protein Custom Protein
Custom Antibody Custom Antibody
Antibody Matched Pairs Antibody Matched Pairs
Antibody & Corresponding Blocking Peptide Pairs Antibody Peptide Pairs
Phospho-Specific Antibodies Phospho Antibodies
Products by Disease Products by Disease
Products by Pathway Products by Pathway
Products by Tissue Products by Tissue

arrow Advanced Search
arrow Submit Technical Q&A
arrow International Distributors
arrow Contact Us
separator
Our Best Sellers moreseparator
separator
 • Heparan Sulphate Proteoglycan (HSPG) ELISA Kit
 • 15-epi-Lipoxin A4 (15-epi-LXA4) ELISA Kit
 • cartilage oligomeric matrix protein (COMP) ELISA Kit
 • PD-L1 Cell Line
 • Soluble protein-100B, S-100B ELISA Kit
 • Karyopherin Alpha 2 (KPNa2) Antibody
 • ACVR1B Blocking Peptide
 • NCAM - CD56 Antibody
 • Clara cell Specific protein CC16 ELISA Kit
 • T-box transcription factor TBX15 Recombinant Protein
 • Cardiolipin IgM ELISA Kit
 • C-telopeptide of Collagen alpha-1(II) chain (CTXII) ELISA Kit
 • ISCU cDNA Clone
 • Phosphoglucomutase (PGM) ELISA Kit
 downarrow more ...
separator
separator
DatasheetFull DatasheetPrinter Friendly DatasheetPrint This DatasheetAdd to Compare ListHave Questions? Ask UsRequest for a Quotation today

anti-PARK2 antibody :: Parkin Antibody

Scan QR to view Datasheet Catalog #    MBS555290
Testing Data
Unit / Price
0.1 mL  /  $495 +1 FREE 8GB USB
 
 Go to:   rightarrow  Product Names   rightarrow Product Info   rightarrow Accession #s   rightarrow Product Desc   rightarrow Diseases/Tissues/Pathways   rightarrow Applications   rightarrow References 
 Product Name   

Parkin (PARK2), Antibody

★Popular Item★
 Also Known As   

Parkin, Affinity Purified Antibody, Rabbit

 Product Gene Name   

anti-PARK2 antibody

[Similar Products]
 Research Use Only    For Research Use Only. Not for use in diagnostic procedures.
Table BarTOPTable Bar
 OMIM    168600
Section Bar
 Species Reactivity    Human, Mouse, Rat
Section Bar
 Form/Format    Liquid in 10 mM sodium HEPES (pH 7.5), 150 mM NaCI, 100 ug BSA and 50% Glycerol.
Section Bar
 Type Info    Rabbit IgG
 Immunogen Sequence    synthetic peptide (KLH coupled) corresponding to residues around amino acid 400 of human parkin.l Antibodies are purified by protein A and peptide aff i nity chromatography.
Section Bar
 Preparation and Storage    Store at -20C. Do not aliquot.
 Other Notes    Small volumes of anti-PARK2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Table BarTOPTable Bar
 Product Categories/Family for anti-PARK2 antibody    Antibodies; Cancer; Parkin
 Applications Tested/Suitable for anti-PARK2 antibody   

Immunocytochemistry (ICC), Western Blot (WB), Immunoprecipitation (IP)

 Application Notes for anti-PARK2 antibody    Western blotting: 1:1000
Immunoprecipitation: 1:50
Immunocytochemistry: 1:600
Dilutions listed only as recommendation. Optimal dilution should be determined by investigator.
Section Bar
 Testing Data of anti-PARK2 antibody    anti-PARK2 antibody Testing Data image
Table BarTOPTable Bar
NCBI/Uniprot data below describe general gene information for PARK2. It may not necessarily be applicable to this product.
 NCBI GI #    3063388
 NCBI GeneID    5071
 NCBI Accession #    BAA25751.1 [Other Products]
Section Bar
 UniProt Secondary Accession #    Q5TFV8; Q5VVX4; Q6Q2I6; Q8NI41; Q8NI43; Q8NI44; Q8WW07; A3FG77; A8K975; D3JZW7; D3K2X0 [Other Products]
 UniProt Related Accession #    O60260 [Other Products]
Table BarTOPTable Bar
 NCBI Official Full Name    Parkin
 NCBI Official Synonym Full Names    parkin RBR E3 ubiquitin protein ligase
 NCBI Official Symbol    PARK2 [Similar Products]
 NCBI Official Synonym Symbols   
PDJ; PRKN; AR-JP; LPRS2
[Similar Products]
 NCBI Protein Information    E3 ubiquitin-protein ligase parkin
 UniProt Protein Name    E3 ubiquitin-protein ligase parkin
 UniProt Synonym Protein Names   
Parkinson juvenile disease protein 2; Parkinson disease protein 2
 Protein Family    Parkin coregulated gene protein
 UniProt Gene Name    PARK2 [Similar Products]
 UniProt Synonym Gene Names    PRKN; Parkin; Parkinson disease protein 2 [Similar Products]
 UniProt Entry Name    PRKN2_HUMAN
Section Bar
 NCBI Summary for PARK2    The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008]
Section Bar
 UniProt Comments for PARK2    PARK2: a component of a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'- linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene. Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING- type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1. Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis. Found in serum. Belongs to the RBR family. Parkin subfamily. 6 isoforms of the human protein are produced by alternative splicing.

Protein type: Ubiquitin ligase; Ubiquitin conjugating system; EC 6.3.2.-; EC 6.3.2.19; Ligase

Chromosomal Location of Human Ortholog: 6q25.2-q27

Cellular Component: Golgi apparatus; neuron projection; mitochondrion; perinuclear region of cytoplasm; endoplasmic reticulum; cytoplasm; SCF ubiquitin ligase complex; cytosol; nucleus; ubiquitin ligase complex

Molecular Function: tubulin binding; identical protein binding; ubiquitin binding; zinc ion binding; histone deacetylase binding; ubiquitin-protein ligase activity; Hsp70 protein binding; actin binding; protein kinase binding; PDZ domain binding; protein binding; G-protein-coupled receptor binding; ubiquitin conjugating enzyme binding; ubiquitin protein ligase binding; chaperone binding; heat shock protein binding; kinase binding; SH3 domain binding; ligase activity

Biological Process: protein monoubiquitination; negative regulation of JNK cascade; proteasomal ubiquitin-dependent protein catabolic process; negative regulation of actin filament bundle formation; central nervous system development; protein polyubiquitination; startle response; adult locomotory behavior; regulation of protein ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; regulation of neurotransmitter secretion; protein ubiquitination; mitochondrion localization; norepinephrine metabolic process; dopamine metabolic process; regulation of dopamine secretion; negative regulation of insulin secretion; negative regulation of glucokinase activity; zinc ion homeostasis; negative regulation of protein amino acid phosphorylation; regulation of lipid transport; dopamine uptake; negative regulation of neuron apoptosis; positive regulation of DNA binding; mitochondrion organization and biogenesis; synaptic transmission, glutamatergic; mitochondrial fission; protein autoubiquitination; positive regulation of I-kappaB kinase/NF-kappaB cascade; protein stabilization; transcription, DNA-dependent; learning; regulation of protein transport; cellular protein catabolic process; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; mitochondrion degradation; regulation of autophagy; positive regulation of transcription from RNA polymerase II promoter; response to oxidative stress

Disease: Parkinson Disease 2, Autosomal Recessive Juvenile; Lung Cancer; Leprosy, Susceptibility To, 2; Ovarian Cancer
Table BarTOPTable Bar
 Research Articles on PARK2    1. A critical requirement for the Ubl domain in substrate ubiquitylation and also demonstrate that Ser65 phosphorylation by PINK1 stimulates ubiquitin discharge from the E2 ligase UbcH7.
Table BarTOPTable Bar
 Precautions    All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
 Disclaimer    While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Table BarTOPTable Bar
Products associated with anti-PARK2 antibodyPathways associated with anti-PARK2 antibody
 Reference Product  PubMed Publications
 PINK1 antibody  >663 publications with PARK2 and PINK1
 UBC antibody  >104 publications with PARK2 and UBC
 SNCAIP antibody  >67 publications with PARK2 and SNCAIP
 GPR37 antibody  >24 publications with PARK2 and GPR37
 UBE2L3 antibody  >11 publications with PARK2 and UBE2L3
 PSMD4 antibody  >3 publications with PARK2 and PSMD4
 UBE2N antibody  >2 publications with PARK2 and UBE2N
 UBE2G1 antibody  >1 publications with PARK2 and UBE2G1
 Products by Pathway  Pathway Diagram
 Adaptive Immune System Pathway antibodies  Adaptive Immune System Pathway Diagram
 Alpha-synuclein Signaling Pathway antibodies  Alpha-synuclein Signaling Pathway Diagram
 Amyloid Fiber Formation Pathway antibodies  Amyloid Fiber Formation Pathway Diagram
 Antigen Processing: Ubiquitination & Proteasome Degradation Pathway antibodies  Antigen Processing: Ubiquitination & Proteasome Degradation Pathway Diagram
 Class I MHC Mediated Antigen Processing & Presentation Pathway antibodies  Class I MHC Mediated Antigen Processing & Presentation Pathway Diagram
 Immune System Pathway antibodies  Immune System Pathway Diagram
 Metabolism Of Proteins Pathway antibodies  Metabolism Of Proteins Pathway Diagram
 Mitophagy Pathway antibodies  Mitophagy Pathway Diagram
 Parkin-Ubiquitin Proteasomal System Pathway antibodies  Parkin-Ubiquitin Proteasomal System Pathway Diagram
 Parkinson's Disease Pathway antibodies  Parkinson's Disease Pathway Diagram
Diseases associated with anti-PARK2 antibodyOrgans/Tissues associated with anti-PARK2 antibody
 Disease Name  Pubmed Publications
 Parkinsonian Disorders Antibodies  >63993 publications with PARK2 and Parkinsonian Disorders
 Nervous System Diseases Antibodies  >63662 publications with PARK2 and Nervous System Diseases
 Movement Disorders Antibodies  >63636 publications with PARK2 and Movement Disorders
 Brain Diseases Antibodies  >63517 publications with PARK2 and Brain Diseases
 Parkinson Disease Antibodies  >56584 publications with PARK2 and Parkinson Disease
 Parkinson Disease, Secondary Antibodies  >6894 publications with PARK2 and Parkinson Disease, Secondary
 Disease Models, Animal Antibodies  >5450 publications with PARK2 and Disease Models, Animal
 Cognition Disorders Antibodies  >3859 publications with PARK2 and Cognition Disorders
 Neurotoxicity Syndromes Antibodies  >3589 publications with PARK2 and Neurotoxicity Syndromes
 Cardiovascular Diseases Antibodies  >3137 publications with PARK2 and Cardiovascular Diseases
 Organ/Tissue Name  Pubmed Publications
 Brain Antibodies  >28219 publications with PARK2 and Brain
 Eye Antibodies  >1191 publications with PARK2 and Eye
 Adrenal Gland Antibodies  >443 publications with PARK2 and Adrenal Gland
 Mouth Antibodies  >297 publications with PARK2 and Mouth
 Kidney Antibodies  >226 publications with PARK2 and Kidney
 Stomach Antibodies  >108 publications with PARK2 and Stomach
 Connective Tissue Antibodies  >65 publications with PARK2 and Connective Tissue
 Prostate Antibodies  >48 publications with PARK2 and Prostate
 Testis Antibodies  >25 publications with PARK2 and Testis
 Placenta Antibodies  >12 publications with PARK2 and Placenta
Table BarTOPTable Bar
horiz bar
 SSL   Follow us on Facebook Follow us onTwitter Follow us on Google Plus Connect us on LinkedIn Subscribe to our RSS Feed for latest products and special promotions